News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
MacuSight, Inc. Raises $8 Million, Bringing Total Series A To $25.5 Million
September 27, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MacuSight Inc., a developer of therapeutics for severe ocular diseases and conditions, has secured $8 million in Series A funding from its investors to further clinical trials for its main ocular disease treatments.
Twitter
LinkedIn
Facebook
Email
Print
Startups
MORE ON THIS TOPIC
Pain
AbbVie enters world of pain in up to $715M deal with China’s Haisco
April 13, 2026
·
1 min read
·
Annalee Armstrong
Radiopharmaceuticals
Regeneron enters radiopharma ring with up to $4.3B Telix alliance
April 13, 2026
·
2 min read
·
Tristan Manalac
Complete response letters
Second rejection for tumor destroyer puts Replimune on a ‘challenging path’
April 13, 2026
·
2 min read
·
Tristan Manalac
IPO tracker
Seaport, Hemab set sail for Nasdaq
April 13, 2026
·
9 min read
·
Tristan Manalac
